Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Interest & Investment Income (2021 - 2025)

Lyra Therapeutics has reported Interest & Investment Income over the past 5 years, most recently at $169000.0 for Q4 2025.

  • Quarterly results put Interest & Investment Income at $169000.0 for Q4 2025, down 61.15% from a year ago — trailing twelve months through Dec 2025 was $1.1 million (down 61.62% YoY), and the annual figure for FY2025 was $1.1 million, down 61.62%.
  • Interest & Investment Income for Q4 2025 was $169000.0 at Lyra Therapeutics, down from $256000.0 in the prior quarter.
  • Over the last five years, Interest & Investment Income for LYRA hit a ceiling of $1.3 million in Q4 2023 and a floor of $14000.0 in Q1 2022.
  • Median Interest & Investment Income over the past 5 years was $354000.0 (2025), compared with a mean of $486350.0.
  • Biggest five-year swings in Interest & Investment Income: surged 7557.14% in 2023 and later plummeted 72.56% in 2025.
  • Lyra Therapeutics' Interest & Investment Income stood at $21000.0 in 2021, then skyrocketed by 4342.86% to $933000.0 in 2022, then soared by 43.41% to $1.3 million in 2023, then tumbled by 67.49% to $435000.0 in 2024, then tumbled by 61.15% to $169000.0 in 2025.
  • The last three reported values for Interest & Investment Income were $169000.0 (Q4 2025), $256000.0 (Q3 2025), and $410000.0 (Q2 2025) per Business Quant data.